featured
ASCO: Outcomes of Patients With Metastatic Urothelial Carcinoma Following Discontinuation of Enfortumab-Vedotin
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: